Oramed trial of diabetes drug delivery tech enrolling patients; Feds give NYU grant to study siRNA;

> Israel's Oramed ($ORMD) said enrollment in the Phase IIb study of its drug delivering capsule for Type 2 diabetes is more than halfway complete. More

> The National Science Foundation awarded New York University's Polytechnic School of Engineering a three-year $300,000 grant to study drug delivery related to siRNA. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.